The COVID-19 pandemic thrust messenger RNA (mRNA) vaccines into the global spotlight, marking a pivotal moment in medical history. Following an expedited yet rigorous clinical trial process, the first COVID-19 mRNA vaccine was administered on December 8, 2020. Over its inaugural year, these innovative vaccines demonstrated an unprecedented impact, with researchers later estimating through sophisticated modeling that they averted at least 14.4 million deaths worldwide. This staggering figure underscores the profound public health benefit and transformative potential of mRNA technology. The undeniable success of mRNA vaccines in curbing the devastating effects of SARS-CoV-2 swiftly spurred scientific interest in applying this technology to combat a broader spectrum of infectious diseases. A flurry of research and development initiatives commenced, with ongoing clinical trials now exploring mRNA vaccine candidates for pervasive threats such as influenza virus, Respiratory Syncytial Virus (RSV), and human immunodeficiency virus (HIV). Beyond these, the technology is being investigated for Zika virus, Epstein-Barr virus, and even challenging bacterial pathogens like tuberculosis. However, parallel to this expansion, extensive studies of the COVID-19 mRNA vaccines themselves have concurrently illuminated important limitations, signaling a critical need for new, complementary, or even superior vaccine strategies to address persistent challenges. Navigating the Complexities: Performance and Production Hurdles for mRNA Vaccines Despite their initial triumphs, the widespread deployment of COVID-19 mRNA vaccines has brought to light several inherent challenges related to their performance and practical implementation. One significant issue is the variability and durability of immune protection. The level of immune response generated by COVID-19 mRNA vaccines can differ widely among individuals, influenced by factors such as age, genetic predisposition, pre-existing immunity, and underlying health conditions. Furthermore, the protection conferred is not indefinite; antibody titers naturally wane over time, and the persistence of cellular immune responses can also vary, necessitating booster doses to maintain adequate immunity. This challenge is compounded by the relentless evolutionary pressure on SARS-CoV-2, which continuously generates new variants. These variants, through mutations in their spike protein, can partially evade existing immune defenses, rendering initial vaccine formulations less effective and mandating frequent updates to vaccine compositions, much like the annual adjustments made for influenza vaccines. Beyond immunological complexities, mRNA vaccines present substantial practical and logistical hurdles. Manufacturing mRNA vaccines is a highly intricate and resource-intensive process. The synthesis of mRNA molecules requires precise enzymatic reactions and stringent quality control. Subsequent encapsulation of these delicate mRNA strands into lipid nanoparticles (LNPs) is equally challenging, demanding sophisticated microfluidic systems to ensure uniform size, stability, and efficient packaging of the mRNA cargo. Controlling the precise number of mRNA molecules per LNP remains a difficult feat, impacting consistency and efficacy. These manufacturing complexities contribute significantly to the high cost of production, potentially limiting global accessibility, particularly in low-income countries. Perhaps one of the most widely recognized practical limitations is the requirement for ultra-cold storage. mRNA vaccines, particularly the early formulations, necessitated storage at temperatures as low as -70°C, posing immense logistical challenges for distribution. Establishing and maintaining a robust "cold chain"—a system of temperature-controlled storage and transport—from manufacturing sites to vaccination points globally proved to be an enormous undertaking, particularly in regions with limited infrastructure, unreliable power grids, or remote populations. This requirement severely hampered equitable access and efficient deployment. Moreover, while generally safe, mRNA vaccines may occasionally cause unintended off-target effects, though these are typically mild and transient. Addressing these multifaceted limitations is paramount to bolstering the world’s preparedness and response capabilities for future infectious disease pandemics. Introducing DoriVac: A DNA Origami Nanotechnology Solution In response to these pressing issues, a pioneering multidisciplinary team, encompassing researchers from the Wyss Institute at Harvard University, Dana-Farber Cancer Institute (DFCI), and their partner institutions, embarked on an exploration of an entirely different approach. Their innovation centers on a novel DNA origami nanotechnology platform known as DoriVac. This sophisticated platform distinguishes itself by functioning simultaneously as both a vaccine and an integrated adjuvant, a substance that enhances the immune response to an antigen. The DoriVac platform is built upon the principles of DNA nanotechnology, where DNA strands are meticulously folded into precise, self-assembling three-dimensional nanostructures. In the context of DoriVac, these structures take the form of tiny, square DNA nanostructures, approximately 50 nanometers in width. Critically, these nanostructures are designed with distinct functional faces. One side is engineered to precisely display immune-stimulating adjuvant molecules, arranged at carefully controlled nanometer distances. This precise spatial arrangement is crucial for optimal interaction with immune cells. The opposite side of the nanostructure is programmed to present selected antigens, which can be peptides or proteins derived from pathogens or even tumor cells. This exquisite control over vaccine composition and the ability to program immune recognition at a molecular level in targeted immune cells is a hallmark of the DoriVac platform, promising more potent and tailored immune responses. The researchers specifically designed DoriVac vaccines to target a conserved peptide region known as HR2, found within the spike proteins of several formidable viruses, including SARS-CoV-2, HIV, and Ebola. The selection of HR2 as a target antigen is strategic; its conservation across different viral strains and species suggests that a vaccine targeting this region could potentially offer broader protection against evolving pathogens. In initial preclinical studies conducted in mice, the DoriVac SARS-CoV-2 HR2 vaccine elicited robust and comprehensive immune responses. This included strong antibody-driven (humoral) activity, essential for neutralizing circulating viruses, as well as potent T cell-driven (cellular) activity, critical for clearing infected cells and providing long-term memory. From Bench to Bedside: Validating DoriVac in Human Models A perennial challenge in vaccine development lies in the translation of promising results from animal models, particularly mice, to human physiology. Immune responses in mice, while informative, often do not fully recapitulate the intricate complexities of the human immune system, leading to a high attrition rate of otherwise promising treatments during human clinical trials. To bridge this critical translational gap and enhance the predictive power of their research, the team harnessed the Wyss Institute’s cutting-edge microfluidic human Organ Chip technology. Specifically, they utilized a human lymph node-on-a-chip (human LN Chip), an advanced in vitro system that meticulously simulates key aspects of human immune responses within a microfluidic environment. In this sophisticated human model, the SARS-CoV-2 HR2 DoriVac vaccine impressively generated strong antigen-specific immune responses within human cells. The human LN Chip system, refined by co-first author Min Wen Ku and co-corresponding author Girija Goyal, Ph.D., Director of Bioinspired Therapeutics at the Wyss Institute, demonstrated that the DoriVac vaccine effectively activated human dendritic cells (DCs)—critical antigen-presenting cells that initiate immune responses—and significantly amplified their production of inflammatory cytokines, signaling molecules crucial for coordinating immune defenses. Furthermore, the DoriVac vaccine led to a marked increase in the numbers of CD4+ and CD8+ T cells, both of which are central to protective immunity, exhibiting multiple protective functions. These findings provided compelling evidence, in a human-relevant context, for the platform’s potential for human therapeutic applications. Dr. Donald Ingber, M.D., Ph.D., a co-corresponding author and a leading figure in the Organ Chip technology, emphasized the profound implications of these findings: "The predictive capabilities of human LN Chips gave us an ideal testing ground for DoriVac vaccines and the induced, antigen-specific immune cell profiles and activities very likely reflect those that would occur in human recipients of the vaccines. This convergence of technologies enabled us to dramatically raise the chances of success for a new class of vaccines and create a new testbed for future vaccine developments." Dr. Ingber, who also holds positions as the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and the Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard John A. Paulson School of Engineering and Applied Sciences, underscored the strategic advantage of this advanced testing platform. A Head-to-Head Comparison: DoriVac vs. mRNA Vaccines To further validate the DoriVac platform’s potential, the researchers conducted a direct comparison against established mRNA vaccines. Led by Yang Zeng and co-author Qiancheng Xiong, the team evaluated a DoriVac vaccine engineered to present the full SARS-CoV-2 spike protein. This DoriVac formulation was pitted against commercially available mRNA lipid nanoparticle (LNP) vaccines from Moderna and Pfizer/BioNTech, which encode the identical spike protein. Using a standard booster vaccination regimen in mice, the results were highly encouraging: both DoriVac and the mRNA-LNP vaccine types produced similarly strong antiviral T cell and antibody-producing B cell responses. This remarkable equivalence in immune activation, as reported in Nature Biomedical Engineering, strongly underscored DoriVac’s potential as a powerful, DNA nanotechnology-enabled, self-adjuvanted vaccine platform. However, beyond mere efficacy, DoriVac vaccines demonstrated several critical advantages that directly address the limitations observed with mRNA-LNP vaccines. Dr. William Shih, Ph.D., a co-corresponding author and Wyss Institute Core Faculty member whose group pioneered the new vaccine concept, highlighted these benefits: "With the DoriVac platform, we have developed an extremely flexible chassis with a number of critical advantages, including an unprecedented control over vaccine composition, and the ability to program immune recognition in targeted immune cells on a molecular level to achieve better responses." He further elaborated on the practical benefits, stating, "DoriVac vaccines don’t have the same cold-chain requirements as mRNA-LNP vaccines do and thus could be distributed much more effectively, especially in under-resourced regions; and they could overcome some of the enormous manufacturing complexities of LNP-formulated vaccines, to name two major ones." Recent studies conducted by DoriNano, a company co-founded by Dr. Zeng to translate this technology, have also indicated that DoriVac exhibits a promising safety profile, further enhancing its appeal. The Genesis of DoriVac: From Cancer to Contagions The journey of DoriVac began not in the realm of infectious diseases, but in oncology. In 2024, Dr. Shih’s team at the Wyss Institute and Dana-Farber initially introduced DoriVac as a DNA nanotechnology-based vaccine platform with broad potential applications for cancer immunotherapy. Dr. Yang (Claire) Zeng, M.D., Ph.D., who led this foundational effort, demonstrated that DoriVac could precisely present immune-stimulating adjuvant molecules to cells at the nanoscale, leading to enhanced anti-tumor immune responses in tumor-bearing mice compared to versions without the DNA origami structure. As Dr. Zeng, now cofounder and CEO/CTO of DoriNano, recalled, "While we were developing the platform for cancer applications, the COVID-19 pandemic was still moving with full force. So, the question quickly arose whether DoriVac’s superior adjuvant activity could also be leveraged in infectious disease settings." This pivotal question initiated a strategic pivot. To explore this new avenue, Dr. Zeng and co-first author Olivia Young, Ph.D., a former graduate student in Dr. Shih’s group, forged a critical collaboration with Dr. Donald Ingber’s team at the Wyss Institute. Dr. Ingber’s group, known for its expertise in antiviral innovation leveraging AI-driven and multiomics approaches alongside microfluidic human Organ Chip systems, provided invaluable resources for infectious disease research. Together with co-first author Longlong Si, Ph.D., a former postdoctoral researcher in Ingber’s lab, the expanded team developed DoriVac vaccines targeting SARS-CoV-2, HIV, and Ebola, specifically presenting the conserved HR2 peptides as antigens. Dr. Zeng highlighted the impactful findings from these early studies: "Our analysis of the immune responses provoked by these first DoriVac vaccines in mice led to several encouraging observations, including significantly greater and broader activation of humoral and cellular immunity across a range of relevant immune cell types than what the origami-free antigens and adjuvants could produce. We found that the numbers of antibody-producing B cells, activated antigen-presenting dendritic cells (DCs), and antigen-specific memory and cytotoxic T cell types that are vital for long-term protection were all increased, especially in the case of the SARS-CoV-2 HR2." These comprehensive immune responses provided a strong foundation for further investigation into DoriVac’s potential for infectious disease prevention. Broader Impact and Future Implications The emergence of the DoriVac DNA origami vaccine platform holds profound implications for the future of vaccinology and global public health. By directly addressing key limitations of current mRNA vaccines, DoriVac represents a potential paradigm shift in how the world prepares for and responds to infectious disease threats. One of the most significant impacts could be on global vaccine accessibility and equity. The enhanced stability of DoriVac vaccines, negating the need for ultracold storage, dramatically simplifies distribution logistics. This is particularly transformative for under-resourced regions and developing countries where maintaining complex cold chains is often impractical or impossible. A vaccine that can be stored at standard refrigeration temperatures or even ambient temperatures would unlock access for millions, fundamentally altering the landscape of vaccine deployment during future pandemics. Furthermore, the potentially simpler and less expensive manufacturing process, compared to the highly complex production of LNP-formulated mRNA vaccines, could lead to more affordable vaccines, further promoting equitable global access. DoriVac’s "flexible chassis" also points to its immense versatility. Its modular design allows for precise presentation of various antigens and adjuvants, making it adaptable for a wide array of infectious diseases, beyond those initially tested. This adaptability could accelerate vaccine development for emerging pathogens, where rapid response is critical. The ability to program immune recognition at a molecular level could also lead to more targeted and potent immune responses, potentially overcoming issues of variable efficacy seen with some current vaccines. For instance, the platform’s capacity to generate both robust humoral and cellular immunity, including long-lasting memory T cells, is crucial for sustained protection against rapidly evolving viruses. The successful validation in human Organ Chip models is another critical step, substantially de-risking the translational path to human clinical trials. This advanced preclinical testing platform could significantly reduce the time and cost associated with vaccine development by providing earlier, more accurate predictions of human immune responses, thus increasing the chances of success in later clinical phases. The collaborative nature of this research, involving multiple institutions and disciplines, underscores the power of integrated scientific effort in tackling complex biomedical challenges. The funding support from diverse sources, including the Wyss Institute, Dana-Farber, National Institutes of Health, US-Japan CRDF global fund, National Research Foundation of Korea, Korea Institute of Science and Technology (KIST), and the Bill and Melinda Gates Foundation, reflects the broad recognition of DoriVac’s potential. While promising, DoriVac is still in its preclinical stages for infectious diseases. The next critical steps will involve further rigorous preclinical studies, followed by the submission of an Investigational New Drug (IND) application to regulatory authorities, paving the way for human clinical trials. The successful translation of this technology, spearheaded by entities like DoriNano, could herald a new era in vaccine design, offering a powerful, accessible, and adaptable tool in the ongoing battle against infectious diseases worldwide. The DoriVac platform represents not just a new vaccine, but a new vision for global health security, built on the precision of nanotechnology. Other authors on the study include Sylvie Bernier, Hawa Dembele, Giorgia Isinelli, Tal Gilboa, Zoe Swank, Su Hyun Seok, Anjali Rajwar, Amanda Jiang, Yunhao Zhai, LaTonya Williams, Caleb Hellman, Chris Wintersinger, Amanda Graveline, Andyna Vernet, Melinda Sanchez, Sarai Bardales, Georgia Tomaras, Ju Hee Ryu, and Ick Chan Kwon. The study has been funded by the Director’s Fund and Validation Project program of the Wyss Institute; Claudia Adams Barr Program at DFCI; National Institutes of Health (U54 grant CA244726-01); US-Japan CRDF global fund (grant R-202105-67765); National Research Foundation of Korea (grants MSIT, RS-2024-00463774, RS-2023-00275456); Intramural Research Program of the Korea Institute of Science and Technology (KIST); and Bill and Melinda Gates Foundation (INV-002274). Post navigation This common vaccine cuts heart risk nearly in half in new study
